RTW: Investing Across Healthcare
What this covers
This Business Breakdowns episode puts Rod Wong and Stephanie Sirota of RTW in conversation with Matt, with Rod carrying most of the explanation. It starts with the mechanics of valuing a drug company. Models need a DCF running about 15 years, since the industry average is 14 years of revenue before patent expiration, and the IRA cuts that to nine years for small-molecule drugs used by the elderly. Stephanie adds the investor-relations side: institutions avoided biotech for its binary outcomes, so RTW spent years educating them.
The science and funding sections cover distinct ground. Rod puts success from first-in-man to approval in the single digits, and says the hard part is knowing which results are predictive. He recounts the SMA pigs recovering after gene therapy as the moment modality change felt real. He also notes that the US averaged about 40 novel approvals a year, then hit a record 61 last year. NIH money is a sliver of a roughly $1 billion drug's cost, and the US is the only market with capital markets deep enough to fund the rest. On GLP-1 drugs, he forecasts a 20% to 30% cardiovascular benefit.
The contested material is policy. Rod argues that about 80% of health costs sit with hospitals and professionals, yet insurers' consolidation after Obamacare left drugmakers as the target of public anger. He says the IRA is pulling capital out of small-molecule oncology, which Stephanie calls a quiet tragedy. He defends M&A as structurally necessary, and he notes that Lilly and Novo have pulled ahead of Pfizer, Roche and others. He also raises antibiotics, where no new drugs have appeared in two decades.
Rod Wong and Stephanie Sirota argue that drug development's three-phase life cycle (a long pre-revenue phase, a stable revenue phase, then an abrupt revenue cliff) makes health care structurally different from other sectors, so investors need phase-specific skills and full-life-cycle, public-private, team-based structures to succeed.
- Drug development has a decade-plus pre-revenue phase, costs $1B+ per drug, and then loses revenue very quickly, forcing companies to constantly reinvent themselves
- Public capital markets in the US are deep enough to fund drug development, and private access to scientific data and management teams creates an advantage for public-private investors
- Policy changes such as the IRA shorten the revenue phase and shift capital away from certain drug categories, while M&A is a structural necessity for replacing expiring revenue
Health care's high entry barriers and option-like biotech valuations demand a distinct investor mindset.
- Unlike cosmetics, where a product can scale through a distributor like L'Oreal, health care has high barriers to both entry and scale, which makes the hurdle even higher and the sector more interesting to investors.
“Here, it's high barrier to entry and high barrier to scale. It's an even higher threshold and a higher hurdle”
- Early-stage biotech models with cash flows ten years out feel like option trades rather than traditional equity valuations, requiring a completely different mindset from investors.
“it feels like an option trade. It's 10 years out, so it's a completely different mindset.”